EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The role of Janus kinase signaling in the pathology of atopic dermatitis

Emma Guttman-Yassky, Alan D Irvine, Patrick M Brunner, Brian S Kim, Mark Boguniewicz, Julie Parmentier, Andrew M Platt, Kenji Kabashima

Journal of Allergy and Clinical Immunology · 2023-12 · 152 (6) · 1394-1404

DOI: 10.1016/j.jaci.2023.07.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-12. Verfasst von Emma Guttman-Yassky und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York. Electronic address: Emma.Guttman@mountsinai.org. Hauptthemen laut MEDLINE: Janus Kinases, Dermatitis, Atopic. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a heterogeneous, chronic, relapsing, inflammatory skin disease associated with considerable physical, psychological, and economic burden. The pathology of AD includes complex interactions involving abnormalities in immune and skin barrier genes, skin barrier disruption, immune dysregulation, microbiome disturbance, and other environmental factors. Many of the cytokines involved in AD pathology, including IL-4, IL-13, IL-22, IL-31, thymic stromal lymphopoietin, and IFN-γ, signal through the Janus kinase (JAK)-signal transducer and activation of transcription (STAT) pathway. The JAK family includes JAK1, JAK2, JAK3, and tyrosine kinase 2; the STAT family includes STAT1, STAT2, STAT3, STAT4, STAT5A/B, and STAT6. Activation of the JAK-STAT pathway has been implicated in the pathology of several immune-mediated inflammatory diseases, including AD. However, the exact mechanisms of JAK-STAT involvement in AD have not been fully characterized. This review aims to discuss current knowledge about the role of the JAK-STAT signaling pathway and, specifically, the role of JAK1 in the pathology and symptomology of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus KinasesDermatitis, AtopicHumansSignal TransductionSTAT Transcription FactorsJanus Kinase 1Cytokines

Stichwörter der Autor:innen

Atopic dermatitisJAK-STATpathologysymptomology

Substanzen

Janus KinasesSTAT Transcription FactorsJanus Kinase 1Cytokines

Autor:innen und Institutionen

  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York. Electronic address: Emma.Guttman@mountsinai.org.
  • Trinity College, Dublin.
  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York.
  • Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver.
  • AbbVie, Inc, North Chicago.
  • Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto.

Förderung

  • AbbVie Inc

Zitieren

APA

Guttman-Yassky, E., Irvine, A. D., Brunner, P. M., Kim, B. S., Boguniewicz, M., Parmentier, J., Platt, A. M., & Kabashima, K. (2023). The role of Janus kinase signaling in the pathology of atopic dermatitis. Journal of Allergy and Clinical Immunology, 152(6), 1394-1404. https://doi.org/10.1016/j.jaci.2023.07.010

Vancouver

Guttman-Yassky E, Irvine AD, Brunner PM, Kim BS, Boguniewicz M, Parmentier J, et al. The role of Janus kinase signaling in the pathology of atopic dermatitis. Journal of Allergy and Clinical Immunology. 2023;152(6):1394-1404. doi:10.1016/j.jaci.2023.07.010

BibTeX
@article{GuttmanYassky2023,
  author = {Guttman-Yassky, Emma and Irvine, Alan D and Brunner, Patrick M and Kim, Brian S and Boguniewicz, Mark and Parmentier, Julie and Platt, Andrew M and Kabashima, Kenji},
  title = {The role of Janus kinase signaling in the pathology of atopic dermatitis},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  volume = {152},
  number = {6},
  pages = {1394--1404},
  doi = {10.1016/j.jaci.2023.07.010}
}
Kostenlos starten →